Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2026-06-24 16:09:57 ET · period of report 2026-06-22 · accession 0001193125-26-281061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-24 16:09 | 2026-06-22 | RLAY | Catinazzo Thomas | CFO | S - Sale+OE | $16.97 | -187.2K | 177.5K | -51% | -$3.18M |
| DMT | 2026-06-24 16:09 | 2026-06-22 | RLAY | Catinazzo Thomas | CFO | M - OptEx | $4.93 | +169.4K | 229.0K | +284% | +$834.7K |
| DMT | 2026-06-24 16:09 | 2026-06-22 | RLAY | Catinazzo Thomas | CFO | M - OptEx | $0.00 | -169.4K | 223.4K | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-22 | S | D | 17,717 | $17.01 | 177,461 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $16.38 to $17.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 9,807 shares underlying restricted stock units. |
| 2 | Common | Common Stock | 2026-06-22 | M | A | 56,323 | $5.04 | 233,784 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F3) Includes 9,807 shares underlying restricted stock units. |
| 3 | Common | Common Stock | 2026-06-22 | S | D | 56,323 | $16.97 | 177,461 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 9,807 shares underlying restricted stock units. |
| 4 | Common | Common Stock | 2026-06-22 | M | A | 61,563 | $5.22 | 239,024 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F3) Includes 9,807 shares underlying restricted stock units. |
| 5 | Common | Common Stock | 2026-06-22 | S | D | 61,563 | $16.97 | 177,461 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 9,807 shares underlying restricted stock units. |
| 6 | Common | Common Stock | 2026-06-22 | M | A | 51,560 | $4.45 | 229,021 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F3) Includes 9,807 shares underlying restricted stock units. |
| 7 | Common | Common Stock | 2026-06-22 | S | D | 51,560 | $16.97 | 177,461 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 9,807 shares underlying restricted stock units. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-06-22 | M | D | 56,323 | $0.00 | 0 | D | $5.04 · — to 2029-04-22 | 56,323 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F5) The shares underlying this stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of April 23, 2019. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-06-22 | M | D | 61,563 | $0.00 | 0 | D | $5.22 · — to 2030-03-01 | 61,563 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F6) On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, vested in sixteen (16) equal quarterly installments following March 11, 2021. |
| 10 | Derivative | Stock Option (Right to Buy) | 2026-06-22 | M | D | 51,560 | $0.00 | 223,440 | D | $4.45 · — to 2035-01-09 | 51,560 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F7) The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. |